Zepbound GoodRx vs Savings Card vs LillyDirect: 2026 Prices

Zepbound GoodRx vs savings card vs LillyDirect: the short answer

Three routes, three gates. If your commercial plan covers Zepbound, use Lilly's commercial savings card. It takes the single-dose pen down to a $25 floor. If your commercial plan does not cover Zepbound, that same card still applies, at a price set by your device: $499 per 1-month fill for the single-dose pen, or a $299 to $449 dose ladder for the KwikPen. If you are uninsured, paying cash, or covered by a government plan, Lilly's separate self-pay card gives you that same KwikPen ladder. In every one of those cases, price a live GoodRx quote alongside it.

One thing to straighten out before the numbers. Lilly's self-pay pricing runs through a savings card, and LillyDirect is Lilly's own pharmacy where you redeem it. That's a fulfilment channel, not a fourth price.

Savings-card figures are labelled by device. GoodRx is shown as a reported range, not a quoted price.

How the Zepbound savings card works

Lilly runs two savings cards, not one. The commercial card, formally the Zepbound Single-Dose Pen and Single-Patient-Use KwikPen Savings Card Program, sits on top of a commercial insurance claim. The Zepbound KwikPen Self-Pay Savings Card Program is for people paying cash, including those on government coverage. What you pay under either turns on your device and, for the KwikPen, your dose.

The $25 covered-commercial tier and its caps

If your commercial plan covers Zepbound, the single-dose pen prices as low as $25 for a 1-month fill. The card contributes up to $100 on a 1-month fill, $200 on a 2-month fill, and $300 on a 3-month fill, with its total contribution capped at $1,300 a year across up to 13 fills (zepbound.lilly.com, 1 September 2026). The $25 is a floor, not a flat price: you pay your copay minus the card contribution, or $25, whichever is higher.

The non-covered tier depends on which device you were prescribed

This is where most confusion starts. If you have commercial insurance that does not cover Zepbound, the card still works, but at a price set by your product presentation, and for the KwikPen by your dose as well:

The fill caps differ for a mechanical reason, not because one number is stale. Lilly defines a month as 28 days of supply. For the single-dose pen that is as many as four pens, and the card allows 13 fills a year. For the KwikPen, one device is a month, and the card allows 11. Same definition, two devices, two counts.

The KwikPen ladder is the part people get wrong most expensively. Read $299, budget for it, and you pay $449 the moment you titrate past 5 mg. Price the rung you expect to sit on for most of the year, which for most people is the top one.

Who the card excludes

Anyone whose prescription drug coverage is government-funded: Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, the Department of Defense, the VA, and TRICARE. The exclusion holds whether or not that coverage actually pays for Zepbound. Note that this closes the commercial card only, not the self-pay one. For enrollment steps and common pharmacy rejection codes, see our Zepbound savings card guide.

Lilly's self-pay card and LillyDirect Pharmacy

Two things get bundled under the name LillyDirect, and separating them makes the pricing legible. The Zepbound KwikPen Self-Pay Savings Card Program is the price. LillyDirect Pharmacy is one place to redeem it, and Lilly lists other pharmacies alongside it, so ordering direct is not the only way to get the self-pay rate.

Current self-pay pricing by dose

Checked on zepbound.lilly.com on 1 September 2026: as low as $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 mg, and $449 at 10 mg, 12.5 mg, and 15 mg. The card covers the single-patient-use KwikPen by NDC. Other administration methods, vials included, are not eligible for savings under it.

One condition carries real money, and it is narrower than it is usually described. The $449 purchase offer applies to the 7.5 mg, 10 mg, 12.5 mg and 15 mg doses only, and holding it requires refilling within 45 days of your previous delivery. At 2.5 mg and 5 mg there is nothing to lose, because the offer price and the regular price are the same $299 and $399.

What you lose by missing it depends on your dose. Against Lilly's regular schedule of $499 at 7.5 mg and $699 at 10 mg and above, a missed refill costs $50 at 7.5 mg and $250 at every dose above it, so the exposure is five times larger on maintenance doses. Set a reminder.

Why the self-pay price beats GoodRx on the figures we could verify

The gap isn't about cutting out the pharmacy, since the self-pay card works at retail pharmacies too. It's about who sets the number. Lilly decides what a cash-paying person pays for its own product and underwrites the difference through the card. A coupon aggregator has no such lever: it can only negotiate against a pharmacy's margin, and on a patented drug with no generic there is not much of it. Novo Nordisk runs the same play for semaglutide, which is why the Wegovy comparison lands in the same place.

Ordering mechanics, pharmacy options, and the device decision are covered in our LillyDirect Zepbound guide.

What GoodRx actually costs for Zepbound

GoodRx's own Zepbound page headlines a price of $299, described as roughly half the average retail price. That figure deserves suspicion for a simple reason. It is the bottom rung of Lilly's own ladder, the 2.5 mg starter price that both Lilly cards quote. A discount-card headline landing exactly on the manufacturer's cheapest starter dose reads like a pointer to that price, not a separately negotiated pharmacy rate. It also flatters the comparison, since almost nobody stays at 2.5 mg for long.

We couldn't confirm it either way. GoodRx blocked our direct page fetch on 1 September 2026, so the per-pharmacy table behind that headline stayed out of reach. Secondary reporting points to a much higher real-world number: roughly $900 to $1,100 per month for the branded pen at retail pharmacies. Treat that as reported, not confirmed.

Patient reports on Zepbound forums describe wide swings, including one account of a coupon cutting a roughly $1,100 pharmacy price to around $500. That is an individual report, not a statistic.

On The Pen walks through the savings card against Lilly's self-pay pricing.

Zepbound GoodRx vs savings card: which eligibility class you are in

Every price above belongs to one of four situations. Find yours, then price only the routes that are open to you.

Four eligibility classes, four different starting points.

• Commercial insurance that covers Zepbound. Use the commercial card. The $25 floor on the single-dose pen beats every other route, and no GoodRx quote will come close.
• Commercial insurance that does not cover Zepbound. The same card still applies. For the single-dose pen that is as low as $499 per 1-month fill. For the KwikPen it is the ladder: $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg up. Price that against a live GoodRx quote for your actual dose, not the starter dose.
• Medicare, Medicaid, or TRICARE. The commercial card is closed, but the self-pay card is not, and it carries the same KwikPen ladder. Check the Medicare GLP-1 Bridge and your formulary too, both in the next section.
• Uninsured or paying cash by choice. The self-pay card is the starting point at $299 to $449 depending on dose. Check a GoodRx quote as a comparison.

Medicare, Medicaid, TRICARE, and the GLP-1 Bridge

Eligible Medicare Part D beneficiaries who meet the clinical criteria and clear prior authorization can get the Zepbound KwikPen at a $50 monthly copay through the CMS Medicare GLP-1 Bridge, live since 1 July 2026 and running through 31 December 2027.

The scope is narrower than most summaries suggest. The Bridge covers the Zepbound KwikPen, not vials and not the single-dose pen. If your prescription is written for either of those, raise it with your prescriber before assuming the $50 applies.

Keep the mechanisms apart. The Bridge is a CMS coverage pathway with its own eligibility gate, not a rung on either Lilly card. It does not reopen the commercial savings card to government beneficiaries. It sits alongside Lilly's self-pay card, which they can use, so a Part D beneficiary who misses the Bridge still has the $299 to $449 KwikPen ladder. Medicaid coverage of weight-management drugs is set state by state, and TRICARE coverage varies by plan and commonly requires prior authorization. Full mechanics live in our Zepbound cost with insurance guide. On the diabetes side of the molecule, the Mounjaro savings card is a separate program with its own terms.

Does the sleep apnea indication change any of this?

Zepbound carries two approved indications: chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity, added in December 2024. Both sit in the same prescribing information, revised April 2026.

Across both Lilly cards and GoodRx, no indication-based pricing difference was found. All three appear to price the same way for any on-label Zepbound prescription. We didn't check that exhaustively against every payer's prior-authorization rules, and those do differ. The variation sits at plan level, not program level: your insurer may want different documentation for a sleep apnea prescription without any of these prices changing.